The role of non-nucleoside reverse transcriptase inhibitors in children with HIV-1 infection

Paediatric Drugs

Volumn 3, Issue 9, 2001, Pages 681-702

  Maddocks, S ^a   Dwyer, D ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANTIRETROVIRUS AGENT; CALCIUM CHANNEL BLOCKING AGENT; CIMETIDINE; CYCLOSPORIN; DELAVIRDINE; DEXAMETHASONE; EFAVIRENZ; KETOCONAZOLE; LIDOCAINE; LOPINAVIR; MACROLIDE; METHADONE; NELFINAVIR; NEVIRAPINE; ORAL CONTRACEPTIVE AGENT; PROTEINASE INHIBITOR; QUINIDINE; QUININE; RIFABUTIN; RIFAMPICIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; UNINDEXED DRUG; WARFARIN;

ADOLESCENT DISEASE; CHILD; DRUG INDUCED DISEASE; HEADACHE AND FACIAL PAIN; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERICUM PERFORATUM; INFECTION PREVENTION; LIVER TOXICITY; NEUROTOXICITY; PERINATAL INFECTION; PRIORITY JOURNAL; RASH; REVIEW; SKIN TOXICITY; SLEEP DISORDER; VERTIGO; VIRUS TRANSMISSION;

EID: 0034777003     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128072-200103090-00006     Document Type: Review

References (132)

1. The changing global epidemiology of HIV infection and AIDS
2. Rates of mother-to-infant transmission of HIV-1 in Africa, America, and Europe: Results from 13 perinatal studies
3. Estimating the timing of mother-to-child transmission of human immunodeficiency virus in the breastfeeding population in Kinshasa, Zaire
4. The sensitivity of HIV-1 DNA polymerase chain reaction in the neonatal period and the relative contributions of intra-uterine and intra-partum transmission
5. Timing of maternal-infant transmission: Associations between intrapartum factors and early polymerase chain reaction results
6. Progress towards elimination of perinatal HIV infection in the United States
7. Risk factors for perinatal transmission of HIV-1 in women treated with zidovudine. PACTG 185
8. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission
9. The ariel project: A prospective cohort study of maternal-child transmission of human immunodeficiency virus type 1 in the era of maternal antiretroviral therapy
10. Estimated timing of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission by use of a Marcov model
11. Defining the time of fetal or perinatal acquisition of human immunodeficiency virus type 1 on the basis of age at first positive culture
12. Risk of human immunodeficiency virus type 1 transmission through breastfeeding
13. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment
14. Perinatal HIV-1 transmission: Recent advances and therapeutic interventions
15. Acceptability and impact of zidovudine for prevention of mother-to-child human immunodeficiency virus-1 transmission in France
16. Perinatal HIV infection and the effect of zidovudine therapy on transmission in rural and urban counties
17. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: A randomised controlled trial
18. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte d'Ivoire: A randomised trial
19. Six month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Côte d'Ivoire and Burkina Faso: A double-blind, placebo-controlled multicentre trial
20. The PETRA study: Early and late efficacy of three short ZDV/3TC combination regimens to prevent mother-to-child transmission of HIV-1
21. Preliminary efficacy, safety, tolerability and pharmacokinetics of short course regimens of nucleoside analogues for the prevention of mother-to-child transmission of HIV
22. Evaluation of safety and efficacy of two simple regimens for the prevention of mother to child transmission (MTCT) of HIV infection: Nevirapine vs lamivudine and zidovudine used in a randomised clinical trial (the SAINT study)
23. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type I: A meta-analysis of 15 prospective cohort studies
24. Elective caesarean section versus vaginal delivery in prevention of vertical HIV-1 transmission: A randomised clinical trial
25. Fatal complications after Caesarian section in HIV-infected women
26. The incidence of complications after caesarian section in 156 HIV-positive women
27. Trends in antiretroviral therapy and mother-infant transmission of HIV
28. Combination of antiretroviral therapy and duration of pregnancy
29. Influence of infant-feeding patterns on early mother-to-child transmission of HIV-1 in Durban, South Africa: A prospective cohort study
30. Effect of breastfeeding and formula feeding on transmission of HIV-1
31. Pretoria pasteurisation: A potential method for the reduction of postnatal mother to child transmission of the human immunodeficiency virus
32. Pasteurisation of HIV contaminated breast milk
33. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States
34. Perinatal transmission of human immunodeficiency virus type-1 by pregnant women with RNA virus loads <1000 copies/ml
35. Persistant mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues
36. Perinatal exposure to zidovudine: Benefits and risks
37. Absence of cardiac toxicity of zidovudine in children
38. Genotypic resistance analysis in women participating in PACTG 316 with HIV-1 RNA <400 copies/mL
39. Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission
40. Viral load and disease progression in infants infected with human immunodeficiency virus type 1
41. HIV-1 dynamics in children
42. Morbidity and mortality in European children vertically infected by HIV-1
43. Natural history of human immunodeficiency virus type 1 infection in children: A five-year prospective study in Rwanda
44. Disease progression in a cohort of infants with vertically acquired HIV infection observed from birth. The Women and Infants Transmission Study (WITS)
45. Evaluation of surrogate markers and clinical outcomes in two-year follow-up of eighty-six human immunodeficiency virus-infected patients
46. Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HIV-infected infants and children
47. Evaluation of human immunodeficiency virus type 1 load, CD4 T-cell level and clinical class as time-fixed and time-varying markers of disease progression in HIV- 1 infected children
48. Disease progression and early viral dynamics in human immunodeficiency virus-infected children exposed to zidovudine during prenatal and perinatal periods
49. Prevention and treatment of pediatric HIV infection
50. Immuno-reconstitution after retroviral therapy in children with HIV infection involves multi-lymphocyte lineages
51. Immune reconstitution and the role of the thymus during potent antiretroviral therapy in vertically HIV-infected children
52. The impact of early initiation of highly active antiretroviral therapy on the human immunodeficiency virus type 1-specific CD8 T cell response in children
53. Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: Control of viral replication and absence of persistent HIV-1-specific immune responses
54. CD4+ and CD8+ T lymphocyte regeneration after anti-retroviral therapy in HIV-1-infected children and adult patients
55. Early immune reconstitution after potent antiretroviral therapy in HIV-infected children correlates with the increase in thymus volume
56. Restoration of CD4+ T-cell count in HIV-1 infected children treated with highly active antiretroviral therapy (HAART) is independent of age
57. Guidelines for the use of antiretroviral agents in pediatric HIV infection
58. Antiretroviral therapy and medical management of pediatric HIV infection
59. Guidelines for antiretroviral therapy for HIV infection
60. Antiviral therapy in childhood
61. Italian guidelines for antiretroviral therapy in children with human immunodeficiency virus-type 1 infection
62. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents
63. What are the special needs of adolescent patients with HIV/AIDS?
64. Nevirapine resistance mutations of human immunodeficiency virus type-1 selected during therapy
65. Nonnucleoside reverse transcriptase inhibitors
66. Mutations in the HIV-1 reverse transcriptase and protease associated with drug resistance
67. Retained effectiveness of protease inhibitor (PI) therapy (Rx) following 'protease sparing' nevirapine/nucleoside (nevirapine/nuc) combination therapy
68. Retrospective analysis of protease inhibitor efficacy among patients failing a delavirdine regimen
69. Antiretroviral therapy and the lipodystrophy syndrome
70. HAART-associated bone mineral loss through increased rate of bone turnover in vertically HIV-infected children
71. HAART-associated changes in body fat distribution and bone mineral loss are detectable in HIV-infected children even in the absence of clinical evidence of lipodystrophy
72. Antiretroviral-associated lipodystrophy syndrome in HIV-infected children
73. Metabolic and body composition changes in HIV-infected children on antiretroviral therapy
74. Nevirapine-containing potent antiretroviral therapy results in anantiatherogenic plasma lipid profile: Results from the Atlantic trial
75. Reversion of lipodystrophy after switching from HIV-1 protease inhibitors to nevirapine
76. Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy
77. Is simplification of HAART safe in HIV-infected children? First Pediatric Switch Study
78. Efavirenz associated breast hypertrophy in HIV infected patients
79. Gynecomastia without lipodystrophy syndrome in HIV-infected men treated with efavirenz
80. Nevirapine: A review of its development, pharmacological profile and potential for use
81. Pharmacokinetics, safety and activity of nevirapine in human immunodeficiency virus type 1-infected children
82. Combination treatment with zidovudine, didanosine and nevirapine in infants with human immunodeficiency virus type 1 infection
83. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006)
84. High-dose nevirapine: Safety, pharmacokinetics and antiviral effect in patients with human immunodeficiency virus infection
85. Is there cross-toxicity between nevirapine and efavirenz in subjects developing rash?
86. The tolerability of efavirenz after nevirapine-related adverse events
87. Interactions among drugs for HIV and opportunistic infections
88. Practical issues in co-administering NNRTIs and PIs
89. Summary of pharmacokinetic drug interaction studies with efavirenz
90. Combination therapy with amprenavir, abacavir, efavirenz in human immunodeficiency virus (HIV)-infected patients failing a PI regimen: Pharmacokinetic drug interactions and antiviral activity
91. Pharmacokinetic interaction of amprenavir in combination with efavirenz or delavirdine in HIV-infected children
92. Assessment of the pharmacokinetic interactions between ABT-378/Ritonavir (ABT-378/r) and efavirenz (EFV) in healthy volunteers and in HIV + subjects
93. Dynamics of human immunodeficiency virus type I replication in vertically infected infants
94. Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase i/ii trial of delavirdine monotherapy (ACTG 260)
95. RT gene mutations associated with resistance to efavirenz
96. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy
97. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy
98. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial
99. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team
100. Efavirenz: Practicalities, considerations and new issues
101. Tolerance of efavirenz in children
102. Efavirenz pregnancy warning
103. Pharmacokinetics of an efavirenz suspension in children
104. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection
105. Impact of introduction of protease inhibitor therapy on reduction in mortality among children and youth infected with HIV-1
106. Kinetic analysis of intravirion reverse transcription in the blood plasma of human immunodeficiency virus type-1 infected individuals: Direct assessment of resistance to reverse transcriptase inhibitors in vivo
107. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial
108. Administration of zidovudine during late pregnancy and delivery to prevent perinatal transmission: Thailand, 1996-1998
109. The one year safety and efficacy data of the HIVNET 012 trial
110. Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa
111. Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhihitors plus nevirapine, nelfinavir, or ritonavir
112. Pharmacokinetics of nevirapine in human immunodeficiency virus type-1 infected pregnant women and their neonates. Pediatric ACTG Protocol 250 team
113. Virologic activity of didanosine, zidovudine and nevirapine combinations in pediatric subjects with advanced HIV disease (ACTG 245)
114. Combinations of ddI, ZDV and NVP can reduce CSF HIV-1 viral load in pediatric patients with advanced HIV disease
115. Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: Week 24 results of a randomised controlled trial
116. Analysis of HIV-1 drug resistance in a randomised controlled trial of a combination of nucleoside analog reverse transcriptase (RT) inhibitors plus nevirapine(NVP), nelfinavir (NFV) or ritonavir (RTV) in stable antiretroviral therapy-experienced HIV-infected children. PACTG 377 study team
117. UK experience of nevirapine in the treatment of HIV-1 infected children
118. Treatment of HIV infected children with delavirdine combined with protease inhihitors: Drug levels, safety and virologic response
119. Combination therapy with efavirenz, nelfinavir and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type-1. PACTG 382 Team
120. HIV-1 DNA persists in PBMC of children on HAART despite prolonged suppression of plasma HIV-1 RNA
121. The SENC trial: Spanish EFV versus NVP comparison trial
122. Choosing the best initial therapy for HIV infection